Neoadjuvant Chemotherapy for Nonmetastatic Esophago-Gastric Adenocarcinomas: A Systematic Review and Meta-Analysis

REFERENCES

• Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2012;62:129–142.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996;5:477–481.
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr , Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583–592.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
   PubMed Web of Science ®Google Scholar
• Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 2010;16:5621–5628.
   PubMed Web of Science ®Google Scholar
• Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van Krieken JH, van de Velde CJ. Chemotherapy for operable gastric cancer: results of the Dutch randomized FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999;35:558–562.
   PubMed Web of Science ®Google Scholar
• GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729–1737.
   PubMed Web of Science ®Google Scholar
• Wu AW, Xu GW, Wang HY, Ji JF, Tang JL. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009;96:26–33.
   PubMed Web of Science ®Google Scholar
• Fareed KR, Ilyas M, Kaye PV, Soomro IN, Lobo DN, Parsons SL, Madhusudan S. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology 2009;55:399–406.
   PubMed Web of Science ®Google Scholar
• Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851–856.
   PubMed Web of Science ®Google Scholar
• Sun XC, Lin J, Ju AH. Treatment of Borrmann type IV gastric cancer with a neoadjuvant chemotherapy combination of docetaxel, cisplatin and 5-fluorouracil/leucovorin. J Int Med Res 2011;39:2096–2102.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721.
   PubMed Web of Science ®Google Scholar
• Nishioka B, Ouchi T, Watanabe S, Umehara M, Yamane E, Yahata K, Muto F, Kojima O, Nomiyama S, Sakita M, Fujita Y, Majima S. Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in stomach cancer. Gan To Kagaku Ryoho 1982;9:1427–1432.
   PubMedGoogle Scholar
• Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohoyama S, Takashima T, Kimura H, Kamata T. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256–261; discussion 261–262.
   PubMed Web of Science ®Google Scholar
• Masuyama M, Taniguchi H, Takeuchi K, Miyata K, Koyama H, Tanaka H, Higashida T, Koishi Y, Mugitani T, Yamaguchi T. Recurrence and survival rate of advanced gastric cancer after preoperative EAP-II intra-arterial infusion therapy. Gan To Kagaku Ryoho 1994;21:2253–2255.
   PubMedGoogle Scholar
• YK Kang, DW Choi, YH Im. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. [Abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1996; No. 503.
   Google Scholar
• Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 1999;46:2035–2038.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kimura T. Long-term outcome of preoperative chemotherapy with 5’-deoxy-5-fluorouridine (5’-DFUR) for gastric cancer. Gan To Kagaku Ryoho 2000;27:1521–1526.
   PubMedGoogle Scholar
• Takiguchi N, Nunomura M, Koda K, Oda K, Suzuki H, Miyazaki M. Neoadjuvant chemotherapy with CDDP and 5-fluorouracil for gastric cancer with serosal invasion. Oncol Rep 2003;10:433–438.
   PubMed Web of Science ®Google Scholar
• Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 2000;7:241–244.
   PubMed Web of Science ®Google Scholar
• Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group. Neo-adjuvant chemotherapy for operable gastric cancer: long-term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643–649.
   PubMed Web of Science ®Google Scholar
• Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer–a single institute study. Anticancer Res 2004;24:1879–1887.
   PubMed Web of Science ®Google Scholar
• Zhang CW, Zou SC, Shi D, Zhao DJ. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol 2004;10:3070–3072.
   PubMed Web of Science ®Google Scholar
• Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol 2010;28:5210–5218.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G; NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw 2010;8:378–409.
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523–1529.
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273–278.
   PubMed Web of Science ®Google Scholar
• Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57–65.
   PubMed Web of Science ®Google Scholar
• Bang Y, Chung H, Xu J. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. [Abstract] J Clin Oncol 2009;27:4556.
   Web of Science ®Google Scholar
• Ichikura T, Tomimatsu S, Uefuji K, Kimura M, Uchida T, Morita D, Mochizuki H. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 1999;86:553–558.
   PubMed Web of Science ®Google Scholar
• Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, Cady J, André T, Gamelin E, de Gramont A. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest 2003;21:14–20.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820.
   Google Scholar
• Shu-Liang Zhao, Jing-Yuan Fang. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest 2008;26:317–325.
   PubMed Web of Science ®Google Scholar
• Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229:303–308.
   PubMed Web of Science ®Google Scholar